EZH2 and prostate carcinoma: However, so far, no attempt has been made to investigate thechanges in the migratory and invasive potential in vitro bysimultaneously treating cells with USP7-specific inhibitor and EZH2 inhibitor.We speculated that the reduction of EZH2 protein by USP7 inhibitor couldmodulate the sensitivity of EZH2 inhibitors in prostate cancer cells.